【摘要】 目的 :研究 2 0名男性健康受试者单剂量口服 75 0mg头孢克洛咀嚼片和胶囊后 ,头孢克洛咀嚼片相对生物利用度。方法 :采用RP HPLC测定人血浆中头孢克洛浓度 ,并用 3P97程序拟合。结果 :单剂量口服 75 0mg头孢克洛咀嚼片和胶囊后的AUC0→ 3 5h分别为 (2 1 90± 3 3 5 ) ,(2 2 4 8± 3 66) μg·h·mL-1;cmax分别是 (18 10± 3 77) ,(18 3 6± 4 0 3 ) μg·mL-1;tmax分别是 (0 70± 0 2 0 ) ,(0 80± 0 2 0 )h ;T1/ 2 分别为 (0 4 9± 0 0 6) ,(0 5 6± 0 17)h ,头孢克洛咀嚼片和胶囊的所有药动学参数经统计学处理均无显著性差异 (P >0 0 5 )。结论 :头孢克洛咀嚼片和胶囊具有生物等效性更多还原

【Abstract】 AIM: To study the pharmacokinetics and bioavailability of cefaclor chewable tablet and capsule in 20 healthy male volunteers after a single oral dose of 750 mg of cefaclor. METHODS: The plasma concentrations of cefaclor were determined by RP HPLC and estimated by 3P97 program. RESULTS: The pharmacokinetic parameters of cefaclor chewable tablet and capsule were as follows: AUC 0→3 5 h (21 90±3 35) μg·h·mL -1 and (22 48±3 66) μg·h·mL -1 ; c max (18 10±3 77) μg·mL -1 and (18 36±4 03) μg·mL -1 ; t max (0 70±0 20) h and (0 80±0 20) h; T 1/2 (0 49±0 06) h and (0 56±0 17) h, respectively. There was no statistical difference between cafaclor chewable tablet and capsule in pharmacokinetic parameters. CONCLUSION: The results show that the 2 preparations are bioequivalent.更多还原